09:13
2026-09-07
cryptobriefing.com
artificial-intelligence
Insilico Medicine’s rentosertib shows potential to slow aging in landmark Phase III trial
Insilico Medicine's AI-designed drug rentosertib, the first oral TNIK inhibitor to reach clinical trials, began Phase III testing on July 7, 2026, across 47 centers in China with approximately 320 pat…